Skip to main content
Clinical Trials/NL-OMON55192
NL-OMON55192
Recruiting
Not Applicable

Exploring bleeding risk and platelet function combined with multiple omics techniques in 22q11.2 deletion syndrome - Platelet function in 22q11.2DS

Medisch Universitair Ziekenhuis Maastricht0 sites60 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
DiGeorge syndrome
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • \- 16 years or older.
  • \- signed informed consent.
  • Adults with 22q11\.2DS
  • \- molecularly confirmed 22q11\.2 deletion syndrome.
  • \- Mentally competent (ability to give informed consent) and aged 16 years and
  • older or, in case
  • the individual is mentally incompetent aged 16 years and older, consent will be
  • given by the legally authorized representative of the subject.

Exclusion Criteria

  • \- The presence of any malignancy.
  • \- Use of antiplatelet or anticoagulant drugs within the last two weeks prior to
  • \- Use of anti\-inflammatory drugs within the last two weeks prior to the study.
  • \- auto\-immune thrombocytopenia
  • Specific for healthy controls:
  • \- A medical history of thrombocytopenia (\<150\.000 platelets per mL).
  • \- Increased bleeding risk, defined as a diagnosed bleeding disorder.
  • \- Metabolic disorder.

Outcomes

Primary Outcomes

Not specified

Similar Trials